Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Secondary Malignant Neoplasm

Cancer Family

Secondary Malignant Neoplasm

CI-CAN-00000346SMNExplore in graph →

4,275 active trials56 approved drugs532 evidence items

NCIt: C4968

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14671
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 226–250 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
· Cancer Discov · 2016 · PMID 27102076 · validated civic_curation pubmed
Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib.
· Front Oncol · 2022 · PMID 36419889 · validated civic_curation pubmed
EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
· Lung Cancer · 2018 · PMID 29290255 · validated civic_curation pubmed
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
· Cancer Discov · 2011 · PMID 22328973 · validated civic_curation pubmed
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
· Cancer Discov · 2011 · PMID 22389872 · validated civic_curation pubmed
Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
· N Engl J Med · 2015 · PMID 26466009 · validated civic_curation pubmed
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
· Cancer Discov · 2015 · PMID 25971939 · validated civic_curation pubmed

Showing 226–250 of 486 publications

← Previous
1
…
9
10
11
…
20
Next →

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

· Lung Cancer · 2012 · PMID 22325357 · validated civic_curation pubmed

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.

· J Clin Oncol · 2016 · PMID 24934779 · validated civic_curation pubmed

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

· J Clin Oncol · 2016 · PMID 26729443 · validated civic_curation pubmed

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

· J Thorac Oncol · 2015 · PMID 25789838 · validated civic_curation pubmed

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

· Nat Commun · 2016 · PMID 26883990 · validated civic_curation pubmed

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

· Cancer Discov · 2015 · PMID 25971938 · validated civic_curation pubmed

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

· J Thorac Oncol · 2014 · PMID 25521405 · validated civic_curation pubmed

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

· Cancer Discov · 2016 · PMID 27048246 · validated civic_curation pubmed

ROS1 rearrangements define a unique molecular class of lung cancers.

· J Clin Oncol · 2012 · PMID 22215748 · validated civic_curation pubmed

Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.

· Genome Biol · 2010 · PMID 20696054 · validated civic_curation pubmed

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

· Clin Lung Cancer · 2015 · PMID 25922291 · validated civic_curation pubmed

Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response.

· Endocrinol Diabetes Metab Case Rep · 2016 · PMID 26788326 · validated civic_curation pubmed

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.

· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.

· Cold Spring Harb Mol Case Stud · 2016 · PMID 27626067 · validated civic_curation pubmed

Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe.

· Hum Genet · 1996 · PMID 8707293 · validated civic_curation pubmed

Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.

· Ann Oncol · 2017 · PMID 28950338 · validated civic_curation pubmed

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.

· Clin Cancer Res · 2016 · PMID 26933125 · validated civic_curation pubmed

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.

· J Natl Compr Canc Netw · 2017 · PMID 28874593 · validated civic_curation pubmed